Natera (NASDAQ:NTRA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $250.00 to $285.00. They now have a "buy" rating on the stock.
Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
I-SPY 2 Publication in Nature Communications Shows Signatera™ Can Predict Treatment Response and Recurrence Risk in Early-Stage Breast Cancer
Natera (NASDAQ:NTRA) had its price target raised by analysts at JPMorgan Chase & Co. from $250.00 to $260.00. They now have an "overweight" rating on the stock.